Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase‐4 inhibitors: An analysis of Medicare claims data from 2007 to 2015
- 20 November 2018
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 21 (4) , 854-865
Abstract
Aims: To examine the outcomes of dipeptidyl peptidase‐4 (DPP‐4) inhibitor initiation with and without concurrent metformin treatment. Materials and methods: We identified Medicare enrollees initiating a DPP‐4 inhibitor, a sulphonylurea or a thiazolidinedione. Using propensity‐score‐weighted Poisson models, we evaluated 1‐year cardiovascular (CV) outcome incidence among initiators of DPP‐4 inhibitors versus comparators in subgroups with and without concurrent metformin use, and assessed the interaction between initiation drug and metformin. Outcomes included mortality, non‐fatal myocardial infarction (MI), stroke, and a composite outcome. Results: For the DPP‐4 inhibitor (n = 13 391) versus sulphonylurea (n = 33 206) comparison, rate differences in composite outcome incidence favoured DPP‐4 inhibitors: −2.0/100 person‐years among metformin users (95% confidence interval [CI] −2.7 to −1.3) and − 1.0/100 person‐years (95% CI −1.8 to −0.2) among metformin non‐users. Similar rate difference trends among metformin users and non‐users were seen for mortality (−1.5/100 person‐years [95% CI −2.1 to −0.9] and −0.7/100 person‐years [95% CI −1.4 to 0.0]) and non‐fatal MI (−0.5/100 person‐years [95% CI −0.8, −0.3] and 0.1/100 person‐years [95% CI −0.2 to 0.4]). The interaction between DPP‐4 inhibitor initiation and metformin was statistically significant for non‐fatal MI ( P = 0.008). For the DPP‐4 inhibitor (n = 22 210) versus thiazolidinedione (n = 9517) comparison, rate differences in composite outcome incidence for DPP‐4 inhibitor initiation were −0.6/100 person‐years (95% CI −1.5 to 0.2) among metformin users and 1.0 (95% CI 0.0 to 2.0) among metformin non‐users. Similar rate difference trends among metformin users and non‐users were seen for mortality (−0.5/100 person‐years [95% CI −1.3 to 0.1] and 0.8/100 person‐years [95% CI −0.0 to 1.7]) and non‐fatal MI (−0.1/100 person‐years [95% CI −0.4 to 0.2] and 0.2/100 person‐years [95% CI −0.1 to 0.6]). The interaction between DPP‐4 inhibitor initiation and metformin was statistically significant for the composite outcome ( P = 0.024) and mortality ( P = 0.023). Conclusion: Incidence rate differences in multiple CV outcomes appeared more favourable when DPP‐4 inhibitor initiation occurred in the presence of metformin, suggesting a possible interaction between DPP‐4 inhibitors and metformin.Keywords
Funding Information
- Cecil G. Sheps Center for Health Services Research
- University of North Carolina
- School of Medicine, University of North Carolina at Chapel Hill
This publication has 30 references indexed in Scilit:
- Effects of Adjusting for Instrumental Variables on Bias and Precision of Effect EstimatesAmerican Journal of Epidemiology, 2011
- The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustrationPharmacoepidemiology and Drug Safety, 2011
- Effect of metformin on cardiovascular events and mortality: a meta‐analysis of randomized clinical trialsDiabetes, Obesity and Metabolism, 2011
- Dealing with heterogeneity of treatment effects: is the literature up to the challenge?Trials, 2009
- Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality?Diabetes Care, 2008
- Variable Selection for Propensity Score ModelsAmerican Journal of Epidemiology, 2006
- Accuracy of medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital recordsAmerican Heart Journal, 2004
- Validating Administrative Data in Stroke ResearchStroke, 2002
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983